Home Tags STRO-002

Tag: STRO-002

James Panek Joins Sutro Biopharma’s Board of Directors

James P. Panek, an independent consultant since 2011, providing technical and strategic insights to companies around the world, has joined Sutro Biopharma's Board of...
Featured Image: Boston Public Garden; Boston, MA. Courtesy: © 2017 Fotolia. Used with permission.

Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002...

Initial safety data of STRO-002 shows potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models were presented at the AACR-NCI-EORTC.FRα is overexpressed...

Sutro Confirms IND for Second Cell-Free ADC Targeting Anti-Folate Receptor-α for...

Sutro Biopharma confirmed that the U.S. Food and Drug Administration (FDA) has concluded their 30-day review of the Investigational New Drug (IND) application for...

A New Generation of Precisely Engineered CD74-Targeting ADCs Receive Orphan Drug...

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for STRO-001 for the treatment of multiple myeloma (MM).In the United States,...

Sutro BioPharma and Celgene Refocus Immuno-Oncology Collaboration – Rapidly Advance Promising...

Earlier today Sutro Biopharma and Celgene confirmed that the companies decided to refocusing the 2014 immuno-oncology collaboration with on four programs that are advancing...